首页> 外文期刊>Nature Communications >ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types
【24h】

ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types

机译:ZEB1通过与侵袭性癌症类型中的YAP1相互作用而变成转录激活因子

获取原文
           

摘要

Early dissemination, metastasis and therapy resistance are central hallmarks of aggressive cancer types and the leading cause of cancer-associated deaths. The EMT-inducing transcriptional repressor ZEB1 is a crucial stimulator of these processes, particularly by coupling the activation of cellular motility with stemness and survival properties. ZEB1 expression is associated with aggressive behaviour in many tumour types, but the potent effects cannot be solely explained by its proven function as a transcriptional repressor of epithelial genes. Here we describe a direct interaction of ZEB1 with the Hippo pathway effector YAP, but notably not with its paralogue TAZ. In consequence, ZEB1 switches its function to a transcriptional co-activator of a ‘common ZEB1/YAP target gene set’, thereby linking two pathways with similar cancer promoting effects. This gene set is a predictor of poor survival, therapy resistance and increased metastatic risk in breast cancer, indicating the clinical relevance of our findings.
机译:早期传播,转移和治疗耐药性是侵袭性癌症类型的主要标志,也是癌症相关死亡的主要原因。诱导EMT的转录阻遏物ZEB1是这些过程的关键刺激物,特别是通过将细胞运动的激活与干性和存活特性结合起来。 ZEB1表达与许多类型的肿瘤的侵袭行为有关,但强效作用不能仅通过其作为上皮基因的转录阻遏物的可靠功能来解释。在这里,我们描述了ZEB1与河马途径效应器YAP的直接相互作用,但没有与其旁系TAZ的直接相互作用。因此,ZEB1将其功能切换为“共同的ZEB1 / YAP目标基因集”的转录共激活因子,从而将两条途径具有相似的促癌作用。该基因集可预测乳腺癌的不良生存,治疗耐药性和转移风险,表明我们发现的临床意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号